Key Points
- To review the efficacy, safety profiles, and implementation strategies of pharmacologic and mechanical thromboprophylaxis in medically ill, nonsurgical patients.
- Evidence synthesis of randomized controlled trials evaluating pharmacologic thromboprophylaxis against deep venous thrombosis and pulmonary embolism in medically ill patients.
- Comparative safety and efficacy analysis of low-molecular-weight heparin versus unfractionated heparin, alongside evaluation of mechanical prophylaxis devices.
- Pharmacologic prophylaxis significantly reduced deep venous thrombosis (RR = 0.46; 95% CI, 0.36–0.59) and pulmonary embolism (RR = 0.49; 95% CI, 0.33–0.72), accompanied by a nonsignificant increase in bleeding (RR = 1.36; 95% CI, 0.80–2.33).
- Low-molecular-weight heparin exhibited similar efficacy to unfractionated heparin for deep venous thrombosis (RR = 0.85; 95% CI, 0.69–1.06) and pulmonary embolism (RR = 1.05; 95% CI, 0.47–2.38), while significantly reducing major bleeding (RR = 0.45; 95% CI, 0.23–0.85).
Structured PICO
Does pharmacologic prophylaxis reduce deep venous thrombosis and pulmonary embolism in medically ill patients?
PPopulationMedically ill (nonsurgical) patients
IInterventionPharmacologic prophylaxis (including low-molecular-weight heparin and unfractionated heparin) and mechanical prophylaxis (intermittent pneumatic compression devices)
CComparatorNo prophylaxis (for general pharmacologic prophylaxis) or unfractionated heparin (when compared to low-molecular-weight heparin)
OOutcomeDeep venous thrombosis and pulmonary embolismhard clinical
Pharmacologic prophylaxis effectively reduces venous thromboembolism in medically ill patients, with low-molecular-weight heparin preferred over unfractionated heparin due to a lower risk of major bleeding.